1.
WHO. World Health Organization,2016, Fact sheet N°104, March 2016. 2015.
2.
WHO. Guidelines for the programmatic management of drug-resistant tuberculosis. 2008:i.
3.
WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant
tuberculosis. 2015:1-447.
4.
WHO. World Health Organization MDR Fact sheet update November 2015. 2015.
5.
Eshetie S, Gizachew M, Dagnew M, Kumera G, Woldie H, Ambaw F, et al. Multidrug resistant
tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis
treatment: a systematic review and meta-analysis. BMC infectious diseases. 2017;17(1):219.
6.
Weyer K, Mirzayev F, Migliori GB, Van Gemert W, D'Ambrosio L, Zignol M, et al. Rapid
molecular TB diagnosis: evidence, policy making and global implementation of Xpert
MTB/RIF. European Respiratory Journal. 2013;42(1):252-71.
7.
Selgelid MJ, Reichman LB. Ethical issues in tuberculosis diagnosis and treatment.
The international journal of tuberculosis and lung disease : the official journal
of the International Union against Tuberculosis and Lung Disease. 2011;15 Suppl 2:S9-13.
8.
Sharma A, Hill A, Kurbatova E, van der Walt M, Kvasnovsky C, Tupasi TE, et al. Estimating
the future burden of multidrug-resistant and extensively drug-resistant tuberculosis
in India, the Philippines, Russia, and South Africa: a mathematical modelling study.
The Lancet Infectious diseases. 2017;17(7):707-15.
9.
WHO. Global Tuberculosis report. 2016:1-214.
10.
WHO. Use of high burden country lists for TB by WHO in the post-2015 era. 2015:1-22.
11.
Lukoye D, Adatu F, Musisi K, Kasule GW, Were W, Odeke R, et al. Anti-tuberculosis
drug resistance among new and previously treated sputum smear-positive tuberculosis
patients in Uganda: results of the first national survey. PloS one. 2013;8(8):e70763.
12.
Palacios E, Franke M, Munoz M, Hurtado R, Dallman R, Chalco K, et al. HIV-positive
patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART
era. The international journal of tuberculosis and lung disease : the official journal
of the International Union against Tuberculosis and Lung Disease. 2012;16(3):348-54.
13.
Phuong NT, Nhung NV, Hoa NB, Thuy HT, Takarinda KC, Tayler-Smith K, et al. Management
and treatment outcomes of patients enrolled in MDR-TB treatment in Viet Nam. Public
health action. 2016;6(1):25-31.
14.
Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, et al. HIV coinfection
in multidrug- and extensively drug-resistant tuberculosis results in high early mortality.
American journal of respiratory and critical care medicine. 2010;181(1):80-6.
15.
van der Walt M, Lancaster J, Shean K. Tuberculosis Case Fatality and Other Causes
of Death among Multidrug-Resistant Tuberculosis Patients in a High HIV Prevalence
Setting, 2000-2008, South Africa. PloS one. 2016;11(3):e0144249.
16.
Shin SS, Modongo C, Boyd R, Caiphus C, Kuate L, Kgwaadira B, et al. High Treatment
Success Rates Among HIV-Infected Multidrug-Resistant Tuberculosis Patients After Expansion
of Antiretroviral Therapy in Botswana, 2006-2013. Journal of acquired immune deficiency
syndromes (1999). 2017;74(1):65-71.
17.
Heysell SK, Ogarkov OB, Zhdanova S, Zorkaltseva E, Shugaeva S, Gratz J, et al. Undertreated
HIV and drug-resistant tuberculosis at a referral hospital in Irkutsk, Siberia. The
international journal of tuberculosis and lung disease : the official journal of the
International Union against Tuberculosis and Lung Disease. 2016;20(2):187-92.
18.
WHO. Global tuberculosis report 2017. Geneva: World Health Organization; 2017. . 2017:1-249.
19.
NTLP. Report on the Population-based Survey of Prevalence of Tuberculosis Disease
in Uganda: 2014-15. 2015.
20.
USAID/UGANDA MONITORING EVALUATION AND LEARNING PROGRAM. TRACK TB- A mixed methods
assessment strategies, partnerships, leverage points and learnings. 2016:1-131.
21.
MSH. TRACK TB project Baseline Assessment Report 2014:1-88.
22.
UBOS. National population and housing census (2014)-Uganda Bureau of Statistics. 2016:1-108.
23.
MoH. Revised National Strategic Plan 2015/16-2019/20 -March 2017. 2017:1-75.
24.
NTLP. Uganda expansion plan 2012-2016 and operational guidance on programmatic management
of drug resistant TB. 2012.
25.
Oladimeji O, Isaakidis P, Obasanya OJ, Eltayeb O, Khogali M, Van den Bergh R, et al.
Intensive-phase treatment outcomes among hospitalized multidrug-resistant tuberculosis
patients: results from a nationwide cohort in Nigeria. PloS one. 2014;9(4):e94393.
26.
Meressa D, Hurtado RM, Andrews JR, Diro E, Abato K, Daniel T, et al. Achieving high
treatment success for multidrug-resistant TB in Africa: initiation and scale-up of
MDR TB care in Ethiopia--an observational cohort study. Thorax. 2015;70(12):1181-8.
27.
Horter S, Stringer B, Reynolds L, Shoaib M, Kasozi S, Casas EC, et al. "Home is where
the patient is": a qualitative analysis of a patient-centred model of care for multi-drug
resistant tuberculosis. BMC health services research. 2014;14:81.
28.
Brust JC, Shah NS, Scott M, Chaiyachati K, Lygizos M, van der Merwe TL, et al. Integrated,
home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model
of care. The international journal of tuberculosis and lung disease : the official
journal of the International Union against Tuberculosis and Lung Disease. 2012;16(8):998-1004.
29.
Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF
assay for pulmonary tuberculosis and rifampicin resistance in adults. The Cochrane
database of systematic reviews. 2014(1):Cd009593.
30.
Scott LE, McCarthy K, Gous N, Nduna M, Van Rie A, Sanne I, et al. Comparison of Xpert
MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis
in a high HIV prevalence setting: a prospective study. PLoS medicine. 2011;8(7):e1001061.
31.
Theron G, Peter J, van Zyl-Smit R, Mishra H, Streicher E, Murray S, et al. Evaluation
of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV
prevalence setting. American journal of respiratory and critical care medicine. 2011;184(1):132-40.
32.
NTLP. Uganda National Guidelines for the Programmatic Management of Drug-resistant
Tuberculosis, 2nd edition. 2016:1-232.
33.
MSH. TRACK-TB Annual report project year IV, October 1, 2015 – September 30, 2016
2016:1-86.
34.
Kapata N, Chanda-Kapata P, Bates M, Mwaba P, Cobelens F, Grobusch MP, et al. Multidrug-resistant
TB in Zambia: review of national data from 2000 to 2011. Tropical medicine & international
health : TM & IH. 2013;18(11):1386-91.
35.
Rhines AS. The role of sex differences in the prevalence and transmission of tuberculosis.
Tuberculosis (Edinburgh, Scotland). 2013;93(1):104-7.
36.
Holmes CB, Hausler H, Nunn P. A review of sex differences in the epidemiology of tuberculosis.
The international journal of tuberculosis and lung disease : the official journal
of the International Union against Tuberculosis and Lung Disease. 1998;2(2):96-104.
37.
Borgdorff MW, Nagelkerke NJ, Dye C, Nunn P. Gender and tuberculosis: a comparison
of prevalence surveys with notification data to explore sex differences in case detection.
The international journal of tuberculosis and lung disease : the official journal
of the International Union against Tuberculosis and Lung Disease. 2000;4(2):123-32.
38.
Horton KC, MacPherson P, Houben RM, White RG, Corbett EL. Sex Differences in Tuberculosis
Burden and Notifications in Low- and Middle-Income Countries: A Systematic Review
and Meta-analysis. PLoS medicine. 2016;13(9):e1002119.
39.
van den Hof S, Najlis CA, Bloss E, Straetemans M. A systematic review on the role
of gender in tuberculosis control. Report prepared for Tuberculosis Control Programme
(TB CAP) September. 2010.
40.
Rocha C, Montoya R, Zevallos K, Curatola A, Ynga W, Franco J, et al. The Innovative
Socio-economic Interventions Against Tuberculosis (ISIAT) project: an operational
assessment. The international journal of tuberculosis and lung disease : the official
journal of the International Union against Tuberculosis and Lung Disease. 2011;15
Suppl 2:S50-7.
41.
Bieh KL, Weigel R, Smith H. Hospitalized care for MDR-TB in Port Harcourt, Nigeria:
a qualitative study. BMC infectious diseases. 2017;17(1):50.
42.
Isaakidis P, Cox HS, Varghese B, Montaldo C, Da Silva E, Mansoor H, et al. Ambulatory
multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients
in a slum setting in Mumbai, India. PloS one. 2011;6(12):e28066.